Just months after graduating from Y Combinator, H1 Insights

, the LinkedIn for the healthcare industry, has raised $12.9 million in a brand-new round of financing. “It’s a much better way to link the environment, “says co-founder Ariel Katz. The business currently has more than 8 million profiles for healthcare specialists in its database and is creating several countless dollars in income, according to Katz. The company stated it’s seen 350 % growth over the last year and already counts 35 pharmaceutical companies amongst its customers.

By working and scraping public records with healthcare payers, systems and data brokers, H1 has actually accumulated perhaps the most comprehensive profiles of medical professionals and provider, including their competence, interests, publications, area, speaking engagements and participation in scientific trials.

Katz imagines a service that enables doctors to communicate with each other throughout specializeds and a better method for pharmaceutical companies to find physicians that can be relevant to new pharmaceutical trials and treatments.

And the company continues to see growth even with pharmaceutical business freezing their clinical trials. The break out of COVID-19 has actually required most business to stop clinical trials as a lot of patients avoid health centers for nearly whatever however the most crucial medical treatments, but H1 Insights uses services for pharmaceutical companies’ medical affairs department, which are still searching for healthcare authorities to team up with, states Katz.

The company’s $12.9 million Series A round closed in February and was led by Menlo Ventures. Other investors consisted of Baron Davis Enterprises (the eponymous personal financial investment vehicle for the NBA star), ClearPoint Financial Investment Partners, Cloudera co-founder Jeff Hammerbacher, Liquid 2 Ventures (the investment fund established by former NFL superstar Joe Montana), Novartis dRx and Underscore VC.

H1 signed its term sheet in February, but wasn’t required to reprice its round as the pandemic began to spread out. With that money now in hand, the business is poised to go on an enormous hiring spree, says Katz.

“Advances in machine learning and AI are developing brand-new chances to leverage data for a favorable effect on human health,” said Greg Yap, partner at Menlo Ventures, and a brand-new addition to the H1 board. “H1 is harnessing the power of this information and providing a robust platform for pharma, biotech and life sciences business to get in touch with healthcare specialists. Their early traction is appealing and shows that it satisfies a clear need for the industry.”

Article curated by RJ Shara from Source. RJ Shara is a Bay Area Radio Host (Radio Jockey) who talks about the startup ecosystem – entrepreneurs, investments, policies and more on her show The Silicon Dreams. The show streams on Radio Zindagi 1170AM on Mondays from 3.30 PM to 4 PM.